All Stories

  1. Identification of connective tissue disease autoantibodies and a novel autoantibody anti-annexin A11 in patients with “idiopathic” interstitial lung disease

    Article • Clinical Immunology, May 2024, Elsevier

    MD Pilar Rivera Ortega

  2. Adaptive multi-interventional trial platform to improve patient care for fibrotic interstitial lung diseases

    Article • Thorax, March 2024, BMJ

    MD Pilar Rivera Ortega

  3. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet Child & Adolescent Health, March 2024, Elsevier

    MD Pilar Rivera Ortega

  4. Mycophenolate and azathioprine efficacy in interstitial lung disease: a systematic review and meta-analysis

    Article • BMJ Open Respiratory Research, February 2024, BMJ

    MD Pilar Rivera Ortega

  5. Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • Nature Communications, January 2024, Springer Science + Business Media

    MD Pilar Rivera Ortega

  6. Accelerated immune ageing is associated with COVID-19 disease severity

    Article • Immunity & Ageing, January 2024, Springer Science + Business Media

    MD Pilar Rivera Ortega

  7. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial

    Article • The Lancet Respiratory Medicine, January 2024, Elsevier

    MD Pilar Rivera Ortega

  8. Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK

    Article • ERJ Open Research, January 2024, European Respiratory Society (ERS)

    MD Pilar Rivera Ortega

  9. Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury

    Article • Brain Communications, December 2023, Oxford University Press (OUP)

    MD Pilar Rivera Ortega

  10. Long COVID research: an update from the PHOSP-COVID Scientific Summit

    Article • The Lancet Respiratory Medicine, November 2023, Elsevier

    MD Pilar Rivera Ortega

  11. Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study

    Article • The Lancet Respiratory Medicine, November 2023, Elsevier

    MD Pilar Rivera Ortega

  12. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet Diabetes & Endocrinology, October 2023, Elsevier

    MD Pilar Rivera Ortega

  13. Gastrointestinal pirfenidone adverse events in idiopathic pulmonary fibrosis depending on diet: the MADIET clinical trial

    Article • European Respiratory Journal, October 2023, European Respiratory Society (ERS)

    MD Pilar Rivera Ortega

  14. Pulmonary Sequelae of COVID-19: Focus on Interstitial Lung Disease

    Article • Cells, September 2023, MDPI AG

    MD Pilar Rivera Ortega

  15. Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis

    Article • Annals of the American Thoracic Society, September 2023, American Thoracic Society

    MD Pilar Rivera Ortega

  16. Genetic and environmental factors in interstitial lung diseases: current and future perspectives on early diagnosis of high-risk cohorts

    Article • Frontiers in Medicine, August 2023, Frontiers

    MD Pilar Rivera Ortega

  17. Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls

    Article • The Lancet Regional Health - Europe, June 2023, Elsevier

    MD Pilar Rivera Ortega

  18. Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study

    Article • The Lancet Respiratory Medicine, April 2023, Elsevier

    MD Pilar Rivera Ortega, Trudie Chalder

  19. Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, April 2023, Elsevier

    MD Pilar Rivera Ortega, Salman Razvi

  20. Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID

    Article • European Respiratory Journal, March 2023, European Respiratory Society (ERS)

    MD Pilar Rivera Ortega

  21. Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study

    Article • EClinicalMedicine, March 2023, Elsevier

    MD Pilar Rivera Ortega

  22. Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases

    Article • Frontiers in Medicine, February 2023, Frontiers

    MD Pilar Rivera Ortega

  23. Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study

    Article • The Lancet Respiratory Medicine, January 2023, Elsevier

    MD Pilar Rivera Ortega

  24. Residual Lung Abnormalities Following COVID-19 Hospitalization: Interim Analysis of the UKILD Post-COVID Study

    Article • American Journal of Respiratory and Critical Care Medicine, December 2022, American Thoracic Society

    MD Pilar Rivera Ortega

  25. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination

    Article • EBioMedicine, December 2022, Elsevier

    MD Pilar Rivera Ortega, Mark Philip Cassar, Prof. Markus Ralser

  26. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study

    Article • The Lancet Respiratory Medicine, August 2022, Elsevier

    Dr Omer Elneima, MD Pilar Rivera Ortega, Mark Philip Cassar, Prof Nicholas Hart, Prof. Markus Ralser, Trudie Chalder

  27. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis

    Article • The Lancet, July 2022, Elsevier

    MD Pilar Rivera Ortega, Salman Razvi

  28. Los primeros pasos hacia el futuro de la EPID: contribuyendo al conocimiento

    Article • Open Respiratory Archives, July 2022, Elsevier

    MD Pilar Rivera Ortega

  29. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, February 2022, Elsevier

    MD Pilar Rivera Ortega, Salman Razvi

  30. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, January 2022, Elsevier

    Dr Ryan Malcolm Hum, MD Pilar Rivera Ortega, Salman Razvi

  31. Essential Features of an Interstitial Lung Disease Multidisciplinary Meeting: An International Delphi Survey

    Article • Annals of the American Thoracic Society, January 2022, American Thoracic Society

    MD Pilar Rivera Ortega

  32. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study

    Article • The Lancet Respiratory Medicine, November 2021, Elsevier

    MD Pilar Rivera Ortega, Dr Omer Elneima, Prof Nicholas Hart, Prof. Markus Ralser, Trudie Chalder

  33. Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

    Article • BMJ Open Respiratory Research, September 2021, BMJ

    MD Pilar Rivera Ortega

  34. An update on interstitial lung disease

    Article • British Journal of Hospital Medicine, July 2021, Mark Allen Group

    MD Pilar Rivera Ortega

  35. Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service

    Article • Advances in Therapy, July 2021, Springer Science + Business Media

    MD Pilar Rivera Ortega

  36. Smoking cessation: strategies and effects in primary and secondary cardiovascular prevention

    Article • Panminerva Medica, June 2021, Edizioni Minerva Medica

    MD Pilar Rivera Ortega

  37. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

    Article • The Lancet, May 2021, Elsevier

    Dr Ryan Malcolm Hum, MD Pilar Rivera Ortega, Salman Razvi

  38. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, May 2021, Elsevier

    Dr Ryan Malcolm Hum, MD Pilar Rivera Ortega, Salman Razvi

  39. CARTA AL EDITOR SOBRE ARTICULO: Enfermedad pulmonar intersticial difusa asociada a enfermedades autoinmunes

    Article • Revista Uruguaya de Medicina Interna, March 2021, Sociedad Medicina Interna de Uruguay

    MD Pilar Rivera Ortega

  40. Different Faces of Idiopathic Pulmonary Fibrosis With Preserved Forced Vital Capacity

    Article • Archivos de Bronconeumología, March 2021, Elsevier

    MD Pilar Rivera Ortega, Guillermo Suarez-Cuartin

  41. Dexamethasone in Hospitalized Patients with Covid-19

    Article • New England Journal of Medicine, February 2021, New England Journal of Medicine (NEJM/MMS)

    MD Pilar Rivera Ortega, Dr Ryan Malcolm Hum

  42. Reply to Althuwaybi et al.: Hospitalization Outcomes for COVID-19 in Patients with Interstitial Lung Disease: A Potential Role for Aerodigestive Pathophysiology?

    Article • American Journal of Respiratory and Critical Care Medicine, February 2021, American Thoracic Society

    MD Pilar Rivera Ortega

  43. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

    Article • The Lancet, February 2021, Elsevier

    MD Pilar Rivera Ortega, Dr Ryan Malcolm Hum, Dr Omer Elneima, Salman Razvi

  44. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study

    Article • American Journal of Respiratory and Critical Care Medicine, December 2020, American Thoracic Society

    MD Pilar Rivera Ortega, Dr Ahilanandan Dushianthan

  45. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

    Article • New England Journal of Medicine, November 2020, New England Journal of Medicine (NEJM/MMS)

    MD Pilar Rivera Ortega, Dr Ryan Malcolm Hum

  46. Mapping IPF helps identify geographic regions at higher risk for disease development and potential triggers

    Article • Respirology, November 2020, Wiley

    Jaume Bordas-Martinez, MD Pilar Rivera Ortega, Guillermo Suarez-Cuartin

  47. Exploring the Association Between Emphysema Phenotypes and Low Bone Mineral Density in Smokers with and without COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2020, Taylor & Francis

    MD Pilar Rivera Ortega

  48. How consistently do physicians diagnose and manage drug-induced interstitial lung disease? Two surveys of European ILD specialist physicians

    Article • ERJ Open Research, January 2020, European Respiratory Society (ERS)

    James Eaden, MD Pilar Rivera Ortega

  49. Predictive variables to obtain a bronchoalveolar lavage of adequate quality in patients with interstitial lung diseases

    Article • September 2019, European Respiratory Society (ERS)

    MD Pilar Rivera Ortega

  50. The importance of real-life research in respiratory medicine: manifesto of the Respiratory Effectiveness Group

    Article • European Respiratory Journal, September 2019, European Respiratory Society (ERS)

    MD Pilar Rivera Ortega

  51. The characterisation of interstitial lung disease multidisciplinary team meetings: a global study

    Article • ERJ Open Research, April 2019, European Respiratory Society (ERS)

    Dr Giovanni Ferrara, MD Pilar Rivera Ortega

  52. Trabecular bone score in active or former smokers with and without COPD

    Article • PLoS ONE, February 2019, PLOS

    MD Pilar Rivera Ortega

  53. Interstitial Lung Diseases in Developing Countries

    Article • Annals of Global Health, January 2019, Ubiquity Press, Ltd.

    MD Pilar Rivera Ortega

  54. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience

    Article • Therapeutic Advances in Respiratory Disease, January 2018, SAGE Publications

    MD Pilar Rivera Ortega

  55. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort study

    Article • European Respiratory Journal, August 2017, European Respiratory Society (ERS)

    Dr Anoop M Nambiar, Dr Giovanni Ferrara, dr michael perch, Satoshi Ikeda, Dr Tiago M Alfaro, MD Pilar Rivera Ortega